Arkadios Wealth Advisors Lowers Stock Holdings in ICON Public Limited (NASDAQ:ICLR)

Arkadios Wealth Advisors lessened its holdings in ICON Public Limited (NASDAQ:ICLR) by 10.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,162 shares of the medical research company’s stock after selling 131 shares during the period. Arkadios Wealth Advisors’ holdings in ICON Public were worth $244,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ICLR. Icon Wealth Advisors LLC grew its stake in ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after acquiring an additional 11,840 shares in the last quarter. Foyston Gordon & Payne Inc bought a new position in shares of ICON Public during the 3rd quarter valued at about $11,672,000. GAMMA Investing LLC grew its position in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after purchasing an additional 169 shares in the last quarter. Sara Bay Financial bought a new stake in shares of ICON Public in the third quarter worth about $1,143,000. Finally, Steph & Co. lifted its position in shares of ICON Public by 3.7% in the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock worth $327,000 after buying an additional 55 shares in the last quarter. 95.61% of the stock is owned by institutional investors.

ICON Public Stock Down 0.2 %

Shares of NASDAQ ICLR opened at $202.68 on Friday. ICON Public Limited has a 52-week low of $183.38 and a 52-week high of $347.72. The firm has a market capitalization of $16.72 billion, a price-to-earnings ratio of 22.60, a PEG ratio of 1.54 and a beta of 1.20. The stock has a 50 day moving average price of $209.32 and a 200 day moving average price of $264.99. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. ICON Public’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.10 earnings per share. Sell-side analysts expect that ICON Public Limited will post 13.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ICLR. JPMorgan Chase & Co. dropped their price target on ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. TD Cowen dropped their target price on ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a report on Friday, October 25th. Barclays decreased their price target on ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Evercore ISI dropped their price objective on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, William Blair reissued an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ICON Public presently has a consensus rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.